Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Ionis Pharmaceuticals, Inc.”

202 pharma patents match "Ionis Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 202
Index total 30,257
Page 4 / 9

Quick answer

This filtered view shows 202 pharmaceutical patents matching "Ionis Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

202 results for “Ionis Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 11197884

    Modulation of the notch signaling pathway for treatment of respiratory disorders

    Ionis Pharmaceuticals, Inc. · Granted Dec 14, 2021 · Expires Dec 9, 2041

    granted
  2. US 11193128

    Compositions for modulating expression of C9ORF72 antisense transcript

    Ionis Pharmaceuticals, Inc. · Granted Dec 7, 2021 · Expires Dec 2, 2041

    granted
  3. US 11155815

    Compositions and methods for modulating Tau expression

    Ionis Pharmaceuticals, Inc. · Granted Oct 26, 2021 · Expires Oct 21, 2041

    granted
  4. US 11136577

    Methods and compositions for inhibiting PMP22 expression

    Ionis Pharmaceuticals, Inc. · Granted Oct 5, 2021 · Expires Sep 30, 2041

    granted
  5. US 11129844

    Compositions and methods for modulating MECP2 expression

    Ionis Pharmaceuticals, Inc. · Granted Sep 28, 2021 · Expires Sep 23, 2041

    granted
  6. US 11118183

    Modulation of angiopoietin-like 3 expression

    Ionis Pharmaceuticals, Inc. · Granted Sep 14, 2021 · Expires Sep 9, 2041

    granted
  7. US 11116843

    Conjugated antisense compounds and their use

    Ionis Pharmaceuticals, Inc. · Granted Sep 14, 2021 · Expires Sep 9, 2041

    granted
  8. US 11111494

    Compositions for modulating Ataxin 2 expression

    Ionis Pharmaceuticals, Inc. · Granted Sep 7, 2021 · Expires Sep 2, 2041

    granted
  9. US 11084844

    Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom

    Ionis Pharmaceuticals, Inc. · Granted Aug 10, 2021 · Expires Aug 5, 2041

    granted
  10. US 11078486

    Compounds and methods for reducing ATXN2 expression

    Ionis Pharmaceuticals, Inc. · Granted Aug 3, 2021 · Expires Jul 29, 2041

    granted
  11. US 11078485

    Compositions comprising alternating 2′-modified nucleosides for use in gene modulation

    Ionis Pharmaceuticals, Inc. · Granted Aug 3, 2021 · Expires Jul 29, 2041

    granted
  12. US 11072794

    Compositions and their uses directed to huntingtin

    Ionis Pharmaceuticals, Inc. · Granted Jul 27, 2021 · Expires Jul 22, 2041

    granted
  13. US 11058709

    Methods of treating breast cancer

    Ionis Pharmaceuticals, Inc. · Granted Jul 13, 2021 · Expires Jul 8, 2041

    granted
  14. US 11033570

    Modulation of Lnc05 expression

    Ionis Pharmaceuticals, Inc. · Granted Jun 15, 2021 · Expires Jun 10, 2041

    granted
  15. US 11021710

    Compounds and methods for reducing FXI expression

    Ionis Pharmaceuticals, Inc. · Granted Jun 1, 2021 · Expires May 27, 2041

    granted
  16. US 11000595

    Modulators of PCSK9 expression

    Ionis Pharmaceuticals, Inc. · Granted May 11, 2021 · Expires May 6, 2041

    granted
  17. US 10961271

    Methods of modulating KEAP1

    Ionis Pharmaceuticals, Inc. · Granted Mar 30, 2021 · Expires Mar 25, 2041

    granted
  18. US 10927377

    Modulators of APOL1 expression

    Ionis Pharmaceuticals, Inc. · Granted Feb 23, 2021 · Expires Feb 18, 2041

    granted
  19. US 10927372

    Compositions and methods for modulating apolipoprotein C-III expression

    Ionis Pharmaceuticals, Inc. · Granted Feb 23, 2021 · Expires Feb 18, 2041

    granted
  20. US 10912792

    Compounds and methods for modulating angiotensinogen expression

    Ionis Pharmaceuticals, Inc. · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted
  21. US 10907160

    Methods for reducing LRRK2 expression

    Ionis Pharmaceuticals, Inc. · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted
  22. US 10883104

    Compositions and methods for modulating apolipoprotein (a) expression

    Ionis Pharmaceuticals, Inc. · Granted Jan 5, 2021 · Expires Dec 31, 2040

    granted
  23. US 10858657

    Methods for treating hypercholesterolemia

    Ionis Pharmaceuticals, Inc. · Granted Dec 8, 2020 · Expires Dec 3, 2040

    granted
  24. US 10844379

    Conjugated antisense compounds and their use

    Ionis Pharmaceuticals, Inc. · Granted Nov 24, 2020 · Expires Nov 19, 2040

    granted